8-K: Astria Therapeutics Announces Phase 3 Trial Design for Navenibart in Hereditary Angioedema

Astria Therapeutics has unveiled the design of its Phase 3 clinical trial, ALPHA-ORBIT, for navenibart, a potential treatment for hereditary angioedema, featuring both 3-month and 6-month dosing regimens.

Summary

• Astria Therapeutics has announced the planned design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema (HAE).
• The trial will evaluate the efficacy and safety of navenibart administered every 3 months (Q3M) and every 6 months (Q6M).
• The primary analysis will be conducted after a 6-month treatment period.
• The trial is expected to enroll up to 145 patients with Type 1 or Type 2 HAE.
• Patients will be randomized to receive either 600 mg initially followed by 300 mg Q3M, 600 mg Q6M, or placebo.
• The primary endpoint is the time-normalized monthly HAE attack rate at 6 months.
• A key secondary endpoint is the proportion of participants who are attack-free at 6 months.
• The trial is expected to begin in Q1 2025, with top-line results anticipated in early 2027.
• The Phase 3 program includes a long-term extension trial where all patients will receive navenibart.
• The design of the Phase 3 program was informed by feedback from the European Medicines Agency and the FDA.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results and a clear path forward for navenibart. The company's financial position is also strong, contributing to a high sentiment score.

Positives

• The trial design incorporates patient-centric dosing flexibility with both Q3M and Q6M options.
• Navenibart has shown strong efficacy in previous trials with a 90-95% reduction in mean monthly attack rate.
• The company has a strong financial position and is funded through the expected top-line Phase 3 results.
• The trial design reflects feedback from regulators and is intended to support global registration.
• The long-term extension trial will provide continued access to navenibart for patients.

Risks

• There are risks inherent in pharmaceutical research and development, including the possibility of adverse results in clinical trials.
• The results of early-stage trials may not be replicated in later-stage trials.
• The company may not be able to enroll sufficient patients in clinical trials on a timely basis.
• There are risks related to decisions made by regulatory authorities on clinical trial design and submissions.
• The company's ability to manufacture sufficient quantities of drug substance and product is a risk.
• There are risks related to competition and the commercial landscape for HAE treatments.
• The company's ability to manage cash usage and obtain necessary financing is a risk.

Future Outlook

The company anticipates initiating the Phase 3 trial in Q1 2025 and expects top-line results in early 2027. They aim to establish navenibart as a market-leading, first-choice therapy for HAE, and are also advancing their STAR-0310 program for atopic dermatitis.

Management Comments

• Jill C. Milne, Ph.D., Chief Executive Officer, stated that the Phase 3 design reflects feedback from regulators and is intended to support global registration for both Q3M and Q6M administration.
• Christopher Morabito, M.D., Chief Medical Officer, mentioned that the Phase 3 program was designed in collaboration with the patient community and physicians and addresses the importance of providing options to patients.

Industry Context

This announcement is significant in the context of the HAE treatment market, where there is a need for therapies that offer both efficacy and patient convenience. The potential for both Q3M and Q6M dosing with navenibart could provide a competitive advantage over existing treatments.

Comparison to Industry Standards

• The document compares navenibart's efficacy to existing HAE treatments such as lanadelumab (TAKHZYRO), berotralstat (ORLADEYO), garadacimab, and donidalorsen.
• Navenibart showed a 90-95% reduction in mean monthly attack rate in Phase 1b/2 trials, which is comparable to or better than the efficacy of some existing treatments.
• The potential for Q3M and Q6M dosing is a key differentiator, as current market leader TAKHZYRO is dosed every 2 weeks with the potential to extend to every 4 weeks.
• The company aims to position navenibart as a market-leading, first-choice therapy for HAE, leveraging its efficacy and dosing flexibility.

Stakeholder Impact

• Shareholders: The announcement of the Phase 3 trial design and positive clinical data is likely to be viewed favorably by investors.
• Patients: The potential for a new treatment option with flexible dosing is a positive development for HAE patients.
• Employees: The progress of the clinical program and the company's financial stability are positive for employees.
• Physicians: The trial design and potential for a new treatment option are relevant for physicians treating HAE.

Next Steps

• Initiate the ALPHA-ORBIT Phase 3 clinical trial in Q1 2025.
• Conduct the long-term extension trial for navenibart.
• Present Phase 1b/2 data at an upcoming scientific conference.
• Advance the STAR-0310 program for atopic dermatitis, with Phase 1a initiation anticipated in Q1 2025.

Key Dates

Keywords

hereditary angioedema, HAE, navenibart, clinical trial, Phase 3, ALPHA-ORBIT, monoclonal antibody, plasma kallikrein, dosing flexibility, biopharmaceutical